| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514483000 | Plural N-C(=X)-X groups | 13 |
| 20080200542 | Benzoyl-Substituted Serineamides - The present invention relates to benzoyl-substituted serineamides of the formula I | 08-21-2008 |
| 20090005442 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS - This invention is directed to a method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): | 01-01-2009 |
| 20090036523 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME - Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders. | 02-05-2009 |
| 20090105334 | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain - This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): | 04-23-2009 |
| 20090111871 | FELBAMATE WITH IMPROVED BULK DENSITY - A synthesis and purification of felbamate, an anticonvulsant, are provided. The product of the synthesis and purification is with high untapped and tapped bulk densities, which increase ease of handling and suitability for use in pharmaceutical formulations. The felbamate may be incorporated into pharmaceutical compositions that can be administered orally for treatment of epilepsy. | 04-30-2009 |
| 20090221700 | Carisprodol Articles and Methods - A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the C | 09-03-2009 |
| 20090234003 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS - This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): | 09-17-2009 |
| 20100099757 | DISULFIRAM DOSES AND TREATMENT REGIMEN SUITABLE FOR TREATMENT OF ANGIOGENESIS-DEPENDENT DISORDERS - A pharmaceutical composition is provided. The pharmaceutical composition includes an amount of disulfuram in unit dosage form which results in a peak serum concentration level which is therapeutically effective in treating an angiogenesis-dependent disorder and can also exhibit minimal or no disulfuram related side effects. | 04-22-2010 |
| 20100144869 | Conjugates Comprising a gaba-or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders - A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed. | 06-10-2010 |
| 20100160428 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS - Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction. | 06-24-2010 |
| 20100261787 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to application of 4,4′-diphenylmethane-bis(methyl)carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-14-2010 |
| 20120270937 | LINEAR SELF-ELIMINATING OLIGOMERS - The present invention relates to a linear self-eliminating oligomer comprising one or more cleavable triggers, linker units, effector units and a carrier, and a pharmaceutical composition comprising said oligomer. | 10-25-2012 |
| 20140336252 | NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration. | 11-13-2014 |
